These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1019153)

  • 1. Binding to plasma lipoproteins of chlorophenoxyisobutyric, tibric and nicotinic acids and their esters.
    Beaumont JL; Dachet C
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):41-3. PubMed ID: 1019153
    [No Abstract]   [Full Text] [Related]  

  • 2. Binding to plasma lipoproteins of chlorophenoxyisobutyric, tibric and nicotinic acids and their esters: its significance for the mechanism of lipid lowering by clofibrate and related drugs.
    Beaumont JL; Dachet C
    Atherosclerosis; 1976; 25(2-3):255-66. PubMed ID: 188431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Transport in blood and mode of action of a hypolipodemic agent related to clofibrate: G P 45.699. Presence in low density serum lipoproteins].
    Beaumont JL; Dachet C; Beaumont V; Buxtorf JC
    Nutr Metab; 1971; 13(6):349-63. PubMed ID: 4337174
    [No Abstract]   [Full Text] [Related]  

  • 4. [Serum gas chromatographic determination of hypolipemic agents derived from clofibric acid].
    Cailleux A; Allain P
    Therapie; 1976; 31(5):631-6. PubMed ID: 1013955
    [No Abstract]   [Full Text] [Related]  

  • 5. [Gas chromatographic analysis of p-chlorphenoxy-isobutyric acid (clofibrate)].
    Knüchel F; Ochs H
    Arzneimittelforschung; 1974 Apr; 24(4):576-8. PubMed ID: 4408060
    [No Abstract]   [Full Text] [Related]  

  • 6. [Comparative effect of pyridine carboxylic and piperidine carboxylic acids on hypercholesteremia and hyperlipoproteinemia induced in rats by injection of Triton WR-1339].
    Freyss-Beguin M; Lechat P
    Therapie; 1968; 23(6):1343-55. PubMed ID: 5713555
    [No Abstract]   [Full Text] [Related]  

  • 7. The primary hyperlipoproteinemias.
    Bybee DE; Hamilton RD
    J Ky Med Assoc; 1974 Dec; 72(12):658-62. PubMed ID: 4373515
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics and hypolipidemic activity of clofibrate-nicotinic acid combinations in rats.
    Cayen MN; Robinson WT; Dubuc J; Dvornik D
    Biochem Pharmacol; 1979 Apr; 28(7):1163-7. PubMed ID: 444274
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacokinetic study in man of hypolipemic agents derived from clofibric acid after single and repeated administration].
    Cailleux A; Allain P; Tadei A
    Therapie; 1976; 31(5):637-45. PubMed ID: 1013956
    [No Abstract]   [Full Text] [Related]  

  • 10. [Serum lipoproteins and antilipemic drugs related to clofibrate. Their in vitro interaction].
    Beaumont JL; Dachet C
    Atherosclerosis; 1973; 17(3):419-33. PubMed ID: 4351719
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical trial of tibric acid, a new hypolipidemic agent].
    Noseda G; Sirtori CR
    Schweiz Med Wochenschr; 1974 Dec; 104(51):1917-22. PubMed ID: 4438990
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hypolipidaemic agents (author's transl)].
    Tillement JP; Albengres E; Choisy H; Millart H
    Nouv Presse Med; 1980 Oct; 9(40):2947-50. PubMed ID: 7443428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein binding of flavoxate and of 3-methylflavone-8-carboxylic acid.
    Conti M; Setnikar I
    Arzneimittelforschung; 1975 Nov; 25(11):1709-12. PubMed ID: 1243078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Arteriosclerosis--nicotinic acid therapy. 2. Alterations in serum lipoproteins. Diagnosis, therapy].
    Gustafson A
    Lakartidningen; 1971 Apr; 68(15):1744-5 passim. PubMed ID: 5577244
    [No Abstract]   [Full Text] [Related]  

  • 15. [Methods of determining principal hypolipidemic agents].
    Moachon G; Houin G; Tillement JP
    Therapie; 1978; 33(5):587-98. PubMed ID: 369027
    [No Abstract]   [Full Text] [Related]  

  • 16. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
    Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
    Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of reserpine to plasma albumin and lipoproteins.
    Chen Z; Danon A
    Biochem Pharmacol; 1979; 28(2):267-71. PubMed ID: 570842
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man and dog.
    Niwa T; Tokuma Y; Noguchi H
    Res Commun Chem Pathol Pharmacol; 1987 Jan; 55(1):75-88. PubMed ID: 3563108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Binding of the reticuloendotheliotropic vital dye-stuffs lithium carmine and trypan blue to plasma proteins].
    Gestewitz HR; Wulf E
    Acta Histochem; 1973; 46(1):18-37. PubMed ID: 4210093
    [No Abstract]   [Full Text] [Related]  

  • 20. [Study of the binding characteristics of chlorophenoxyisobutyric acid to serum proteins in chronically uremic patients : influence of dialysis and heparine (author's transl)].
    Lacour B; Di Giulio S; Nicolaï A; Drüeke T; Debray M; Boulu RG
    Nephrologie; 1982; 3(1):19-22. PubMed ID: 7088259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.